{"id":"https://genegraph.clinicalgenome.org/r/aa0fe148-78e0-490e-a511-41e98799b10cv1.2","type":"EvidenceStrengthAssertion","dc:description":"*TFAP2B* is located on chromosome 6 at 6p12.3 and encodes the transcription factor AP-2β protein which is part of a family of AP-2 transcription factors, all of which play a role in development. Multiple disease entities have been reported in association with this gene: Char syndrome (MIM:169100), patent ductus arteriosus 2 (PDA) (MIM:617035), and syndromic craniosynostosis. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, there was no evidence of differences in molecular mechanism and inheritance pattern between Char syndrome and PDA. Therefore, the following disease entities have been lumped into one disease entity: *TFAP2B*- related congenital heart disease spectrum disorder (MONDO:1010098). The syndromic craniosynostosis assertion has been split and will be curated when additional genetic evidence is published. \n\n*TFAP2B* was first reported in connection with autosomal dominant *TFAP2B*- related congenital heart disease spectrum disorder in 2000 (Satoda et al. 2000 PMID: 10802654). The disorder is characterized by PDA, facial dysmorphism (wide-set eyes, downslanting palpebral fissures, mild ptosis, flat midface, flat nasal bridge and upturned nasal tip, short philtrum with a triangular mouth, and thickened, everted lips), hand anomalies (aplasia or hypoplasia of the middle phalanges of the fifth fingers). Evidence supporting this gene-disease relationship includes case-level data and experimental data.\n\nTwelve variants (7 missense, 3 splice site, 2 frameshift)  reported in 12 probands in seven publications have been included in this curation (PMIDs: 10802654,15684060, 21643846,30579973,18752453, 11505339, 31012281). This gene-disease relationship is also supported by expression data, biochemical function studies, and two non-human model organisms (PMIDs: 21829553, 32878901, 8989526). In summary, there is definitive evidence supporting the relationship between *TFAP2B* and *TFAP2B*- related congenital heart disease spectrum disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. The classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date October 2nd, 2024 (SOP Version 11).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/aa0fe148-78e0-490e-a511-41e98799b10c","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2024-10-02T16:00:00.000Z","role":"Approver"},{"agent":"https://genegraph.clinicalgenome.org/agent/10130","role":"SecondaryContributor"},{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2025-09-25T20:12:42.982Z","role":"Publisher"}],"curationReasons":["DiseaseNameUpdate"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00148cc9-bbfa-4a49-9edd-cce3e63922ca","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00148cc9-bbfa-4a49-9edd-cce3e63922ca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15684060","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c993e2d-66b7-4cbc-8fcc-554a74610c7b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.601+5G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341966"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/00148cc9-bbfa-4a49-9edd-cce3e63922ca_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The c.601+5G>A mutant disrupted transactivation and could not produce any protein, which indicated a haploinsufficient effect involved in the development of isolated PDA.  Ji et al 2014 PMID: 24507797\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eeda2fb9-e512-4ccf-8c02-ec47101d41c4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eeda2fb9-e512-4ccf-8c02-ec47101d41c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11505339","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a6f0630-4b8d-4de4-ad34-11bc9f45c517","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.706C>T (p.Arg236Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340718"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/eeda2fb9-e512-4ccf-8c02-ec47101d41c4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant protein dimerized but failed to bind target sequences in vitro","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/662a9cb6-0dde-4b63-b70e-42f251065108","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/662a9cb6-0dde-4b63-b70e-42f251065108_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31012281","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb9b54d-950f-47a9-bfcc-52e242a759f8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.917C>T (p.Thr306Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA364415423"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b5427087-5439-4a20-abd0-1b1c411d5a05","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5427087-5439-4a20-abd0-1b1c411d5a05_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11505339","allele":{"id":"https://genegraph.clinicalgenome.org/r/eb418305-b9ce-4d3d-af27-c1bbd1074881","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.218C>G (p.Pro73Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340721"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b5427087-5439-4a20-abd0-1b1c411d5a05_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"P62R binds DNA normally as a homo- and heterodimer, but fails to transactivate as a homodimer and interferes with transactivation from heterodimeric partners.\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e746a91c-ddc3-4fd0-a22b-541be6fea88f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e746a91c-ddc3-4fd0-a22b-541be6fea88f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10802654","allele":{"id":"https://genegraph.clinicalgenome.org/r/db229931-59d6-4208-a484-9234baeed2d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.824C>A (p.Ala275Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340716"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e746a91c-ddc3-4fd0-a22b-541be6fea88f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant TFAP2B protein dimerized properly in vitro, but showed abnormal binding to TFAP2 target sequence. Dimerization of mutant with normal TFAP2B adversely affected transactivation, demonstrating a dominant-negative mechanism.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/91a6509a-b1bc-4865-9a11-68a6b2dc7ba6","type":"EvidenceLine","dc:description":"Downgraded by 0.5 points because of the consanguineous parents. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91a6509a-b1bc-4865-9a11-68a6b2dc7ba6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18752453","allele":{"id":"https://genegraph.clinicalgenome.org/r/9f1d4f87-007c-4db4-9b6a-08d16c98a2e5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.541-2A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10584060"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/20a9b0e5-65c8-422e-b904-278264f35a8e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20a9b0e5-65c8-422e-b904-278264f35a8e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11505339","allele":{"id":"https://genegraph.clinicalgenome.org/r/c17541ac-0206-43c0-a631-0f7d783da0ea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.854G>A (p.Arg285Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340720"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/20a9b0e5-65c8-422e-b904-278264f35a8e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant protein failed to bind target sequences in vitro.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9df6a249-4448-4643-ad92-e79f37cb7c6c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9df6a249-4448-4643-ad92-e79f37cb7c6c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21643846","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c993e2d-66b7-4cbc-8fcc-554a74610c7b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/9df6a249-4448-4643-ad92-e79f37cb7c6c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The mutant disrupted transactivation and could not produce any protein, which indicated a haploinsufficient effect involved in the development of isolated PDA. Ji et al 2014 PMID: 24507797\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/70b6f7cc-6750-4ab5-a70b-77772c1de6b3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/70b6f7cc-6750-4ab5-a70b-77772c1de6b3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21643846","allele":{"id":"https://genegraph.clinicalgenome.org/r/257b073b-e6b9-41c9-84cc-3cee30be4dc1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.439_442del (p.Pro147ThrfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10584061"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/70b6f7cc-6750-4ab5-a70b-77772c1de6b3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The mutation produced a 21-kD protein which had no impact on the transactivation of the wild-type TFAP2B. Therefore, the mutation did not competitively inhibit the function of the wild-type TFAP2B allele. The mutant would exhibit a dominant negative effect. However, cells co-transfected with c.435_438delCCGG and wild-type plasmids had no change in the luciferase signal, suggesting that this mutation also affects the N-terminal coactivator-binding domain. These results are consistent with a haploinsufficient effect involved in the pathogenesis of familial isolated PDA (Ji et al 2014 PMID: 24507797). ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2ed4764-d326-467b-b91a-910073c28f00_proband_segregation","type":"FamilyCosegregation","dc:description":"Linkage analysis and direct sequencing","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15684060","rdfs:label":"K144","estimatedLodScore":2.41,"family":{"id":"https://genegraph.clinicalgenome.org/r/f2ed4764-d326-467b-b91a-910073c28f00","type":"Family","rdfs:label":"K144","member":{"id":"https://genegraph.clinicalgenome.org/r/82e5864d-9ebe-4368-916a-9fc89cdbf7e0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15684060","rdfs:label":"Mani_K144","ageType":"AgeAtReport","ageUnit":"Years","ageValue":22,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3c993e2d-66b7-4cbc-8fcc-554a74610c7b"},"detectionMethod":"Direct sequencing  ","firstTestingMethod":"PCR","phenotypeFreeText":"Asymptomatic, PDA, no facial dysmorphisms, finger and toe clinodactyly, hypodontia, dysmorphic occipital bone, and somnambulism. Examination of the proband and two affected siblings with PDA revealed facial dysmorphic features in one and finger clinodactyly in all, providing evidence of Char syndrome. Parasomnia (sleepwalking) in 12/23 members \n","secondTestingMethod":"Other","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/00148cc9-bbfa-4a49-9edd-cce3e63922ca_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Asymptomatic, PDA, no facial dysmorphisms, finger and toe clinodactyly, hypodontia, dysmorphic occipital bone, and somnambulism. Examination of the proband and two affected siblings with PDA revealed facial dysmorphic features in one and finger clinodactyly in all, providing evidence of Char syndrome. Parasomnia (sleepwalking) in 12/23 members \n","phenotypePositiveAllelePositive":9,"proband":{"id":"https://genegraph.clinicalgenome.org/r/82e5864d-9ebe-4368-916a-9fc89cdbf7e0"},"publishedLodScore":7.48,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/85e8dc6a-8932-4215-aef1-b602f2aac5f2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85e8dc6a-8932-4215-aef1-b602f2aac5f2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10802654","allele":{"id":"https://genegraph.clinicalgenome.org/r/7dc83e1f-fff0-4f7d-b5ce-88c98ae9613b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.898C>T (p.Arg300Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340717"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/85e8dc6a-8932-4215-aef1-b602f2aac5f2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant TFAP2B protein dimerized properly in vitro, but showed abnormal binding to TFAP2 target sequence. Dimerization of mutant with normal TFAP2B adversely affected transactivation, demonstrating a dominant-negative mechanism","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e79b5520-3d60-4a00-84af-9369fab7e81f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e79b5520-3d60-4a00-84af-9369fab7e81f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11505339","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ad3442e-91f1-4784-8fb4-259bf2a23537","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.706C>A (p.Arg236Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340719"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e79b5520-3d60-4a00-84af-9369fab7e81f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins dimerized but failed to bind target sequences in vitro","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4620beaf-5993-442f-afbb-23ddd3d31980","type":"EvidenceLine","dc:description":"Downgraded by 0.5 points because of the consanguineous parents.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4620beaf-5993-442f-afbb-23ddd3d31980_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30579973","allele":{"id":"https://genegraph.clinicalgenome.org/r/9bd909cf-0d27-43ba-a40d-f0e5ce4fe151","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.650del (p.Gly217AlafsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913189653"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5e10e84e-ecad-44a6-b3d8-5efb97743546","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e10e84e-ecad-44a6-b3d8-5efb97743546_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15684060","allele":{"id":"https://genegraph.clinicalgenome.org/r/b978d01f-498e-4575-9d5d-f4867264a686","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003221.4(TFAP2B):c.822-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341969"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2b0267ab-3f4a-45d1-b471-9142ebd8d809","type":"EvidenceLine","dc:description":"Upgraded based on the evidence showing TFAP2B is expressed in tissues relevant to Char syndrome and PDA (posterior limbs and ductus arteriosus). ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb0c7f34-6384-4e51-a1df-b91f8f21e3d3","type":"Finding","dc:description":"The cardiovascular system of patients with PDA and/or Char syndrome is impacted. Additionally, patients with Char syndrome have hand anomalies. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21829553","rdfs:label":"Tfap2b expression studies","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5ecc9d30-55bd-4ccd-927c-b253dfd2a5a2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b8b6b420-97ba-44a0-9884-c133109c1800","type":"Finding","dc:description":"Neural crest cells are important in the development of several of the tissues affected in Char syndrome. Neural crest cells also emanating from the occipital neural tube are critical for cardiovascular development. PDA in Char syndrome is likely a result of abnormal neural crest development. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9271117","rdfs:label":"In situ hybridization ","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/97afa6a4-1126-4299-b717-7c730ad81526","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8658e733-f546-4de3-add1-8b5e1c177fb2","type":"Finding","dc:description":"Affected patients with mutations in TFAP2B and Char syndrome present with hand anomalies (aplasia or hypoplasia of the middle phalanges of the fifth fingers). \n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21829553","rdfs:label":"Biochemical studies ","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1da86355-6e52-4f93-b437-a970ae45df66_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1ffa719-7cbe-4468-89a8-948a262968e5","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a13b896a-cc7d-400f-a319-6a5e7295d7a8","type":"Finding","dc:description":"PDA and hand anomalies are hallmark features of Char syndrome. Patients with isolated PDA have the cardiovascular phenotype. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21829553","rdfs:label":"Mutant Mice: Tfap2 btm1Rbu/ Tfap2 btm1Rbu ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/07db3cb9-1b37-4161-8d33-a1a892ccb69a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84520d56-c112-4985-8b10-ce3d588c43de","type":"Finding","dc:description":"Mani et al. 2005 PMID: 15684060 reported two families with altered sleep abnormalities segregating with TFAP2B mutations. The affected father and his three children in K145 reportedly sleep only 2–3 hours each night, without signs of daytime fatigue. Additonally, parasomnia (sleepwalking) was reported in 12/23 members in K144.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32878901","rdfs:label":"Tfap2bK144 and Tfap2bK145 mutant mouse strains","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":11849,"specifiedBy":"GeneValidityCriteria11","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/PyoiyjDHSxg","type":"GeneValidityProposition","disease":"obo:MONDO_1010098","gene":"hgnc:11743","modeOfInheritance":"obo:HP_0000006"},"version":"1.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1da86355-6e52-4f93-b437-a970ae45df66-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}